You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Azacitidine improves outcome in higher‐risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
|
|---|---|
| Published in |
British Journal of Haematology, April 2018
|
| DOI | 10.1111/bjh.15190 |
| Pubmed ID | |
| Authors |
María Díez‐Campelo, Jose I. Lorenzo, Raphael Itzykson, Silvia M. Rojas, Céline Berthon, Elisa Luño, Odile Beyne‐Rauzy, Jaime Perez‐Oteyza, Norbert Vey, Joan Bargay, Sophie Park, Teresa Cedena, Dominique Bordessoule, Juan A. Muñoz, Emmanuel Gyan, Esperanza Such, Sorin Visanica, Félix López‐Cadenas, Stéphane de Botton, Jesús M. Hernández‐Rivas, Shanti Ame, Aspasia Stamatoullas, Jacques Delaunay, Celia Salanoubat, Françoise Isnard, Romain Guieze, Joan Pérez Guallar, Llorenc Badiella, Guillermo Sanz, Consuelo Cañizo, Pierre Fenaux |
| Abstract |
Treatment with azacitidine (AZA) has been suggested to be of benefit for higher-risk myelodysplastic syndrome (HR-MDS) patients with chromosome 7 abnormalities (Abn 7). This retrospective study of 235 HR-MDS patients with Abn 7 treated with AZA (n = 115) versus best supportive care (BSC; n = 120), assessed AZA treatment as a time-varying variable in multivariable analysis. A Cox Regression model with time-interaction terms of overall survival (OS) at different time points confirmed that, while chromosome 7 cytogenetic categories (complex karyotype [CK] versus non-CK) and International Prognostic Scoring System risk (high versus intermediate-2) retained poor prognosis over time, AZA treatment had a favourable impact on OS during the first 3 years of treatment compared to BSC (Hazard ratio [HR] 0·5 P < 0·001 at 1 year, 0·7 P = 0·019 at 2 years; 0·73 P = 0·029 at 3 years). This benefit was present in all chromosome 7 categories, but tended to be greater in patients with CK (risk reduction of 82%, 68% and 53% at 1, 3 and 6 months in CK patients; 79% at 1 month in non-CK patients, P < 0·05 for all). AZA also significantly improved progression-free survival (P < 0·01). This study confirms a time-dependent benefit of AZA on outcome in patients with HR-MDS and cytogenetic abnormalities involving chromosome 7, especially for those with CK. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 33% |
| Brazil | 1 | 11% |
| Unknown | 5 | 56% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 89% |
| Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 26% |
| Other | 2 | 11% |
| Student > Postgraduate | 2 | 11% |
| Librarian | 1 | 5% |
| Student > Bachelor | 1 | 5% |
| Other | 3 | 16% |
| Unknown | 5 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 16% |
| Business, Management and Accounting | 2 | 11% |
| Nursing and Health Professions | 1 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Other | 2 | 11% |
| Unknown | 6 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 August 2018.
All research outputs
#6,273,913
of 24,484,013 outputs
Outputs from British Journal of Haematology
#2,281
of 7,897 outputs
Outputs of similar age
#102,829
of 333,259 outputs
Outputs of similar age from British Journal of Haematology
#33
of 107 outputs
Altmetric has tracked 24,484,013 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 7,897 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,259 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 107 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.